IL6 and Castleman disease: Effective anti-IL-6 agents have been developed and, to date, the monoclonal antibodies (mAb) tocilizumab (anti-IL-6R) and siltuximab (anti-IL-6) are approved by the FDA for the treatment of RA and Castleman’s disease, respectively [252].